Dyslipidemia - Drugs

  1. HMG-CoA Inhibitors (Statins) - Drugs
    In order of most potent to least potent: Rosuvastatin (Crestor 5-40), Atorvastatin (Lipitor 10-80), Simvastatin (Zocor 5-80), Pitavastatin (Livalo 1-4), Pravastatin (Pravachol 10-80), Lovastatin/ER (Mevacor 10-80/Altoprev 10-60), Fluvastatin (Lescol 20-80)
  2. HMG-CoA Inhibitors (Statins) - Drug Equivalents
    Rosuvastin 10 = Atorvastatin 20 = Simvastatin 40 = Pravastatin/Lovastatin 80
  3. HMG-CoA Inhibitors (Statins) - Mechanism
    inhibits the rate - limiting step of de novo synthesis of cholesterol
  4. HMG-CoA Inhibitors (Statins) - Adverse Effects
    myalgia, LFT elevation, CK elevation, hepatic failure, rhabdomyolysis
  5. HMG-CoA Inhibitors (Statins) - Monitor
    LFTs, S/Sx of myalgia
  6. HMG-CoA Inhibitors (Statins) - Targets
    LDL (reduce as high as 63%), little effect of HDL
  7. Cholesterol Absorption Inhibitor - Drugs
    Ezetimibe (Zetiia 10)
  8. Cholesterol Absorption Inhibitor - Mechanism
    Inhibits cholesterol absorption at the brush border in the small intestine
  9. Cholesterol Absorption Inhibitor - Adverse Effects
    hepatitis, cholecystitis, cholelithiasis, abdominal pain, diarrhea
  10. Cholesterol Absorption Inhibitor - Target
    LDL (reduce by ~18%)
  11. Niacin - drug in own class
    Niacin - Niaspan (500-2000)
  12. Niacin - Mechanism
    enhances lipoprotein lipase activity, inhibits lipolysis in adipose tissue, decreases VLDL production
  13. Niacin - Adverse Effects
    Flushing, abdominal pain, LFT elevation, N/V, hepatic failure, hyperglycemia, hyperuricemia
  14. Niacin - Monitor
    LFTs, glucose, uric acid
  15. Niacin - Target
    Raises HDL
  16. Fibric Acid Derivatives - Drugs
    Gemfibrozil (Lopid 1200), Fenofibrate (Fenoglide 40-120, Lipofen 50-150, Lofibra Tabs 54-160, Tricor 48-145, Triglide 50-160), Fenofibrate Micronized (Antara 43-130, Lofibra Caps 67-200), Fenofibric Acid (Trilipix 45-135)
  17. Fibric Acid Derivatives - Mechanism
    Inhibits lipolysis in adipose tissue, decreases production and increases clearance of apoB, enhances lipoprotein lipase activity
  18. Fibric Acid Derivatives - Adverse Effects
    dyspepsia, abdominal pain, N/V, diarrhea, elevated LFTs, cholelithiasis, myopathy, thrombocytopenia, anemia
  19. Fibric Acid Derivatives - Monitor
    SCr, LFTs, CBC
  20. Fibric Acid Derivatives - Target
    lower TG, Raise HDL; upregulate protein lipase - affects VLDL production in liver
  21. Bile Acid Sequestran - Drugs
    Colestipol (Colestid 2-16), Colesevelam (Welchol 2500-4375)
  22. Bile Acid Sequestran - Mechanism
    binds intestinal bile acids preventing enterohepatic
  23. Bile Acid Sequestran - Adverse Effects
    esophageal obstruction, bowel obstruction, fecal impaction, dysphagia, constipation, dyspepsia
  24. Bile Acid Sequestran - Target
    LDL (reduce by 15-18%)
  25. Bumblebee Tuna - Drugs
    omega 3 fatty acids (Lovaza 4)
  26. Bumblebee Tuna - Mechanism
    decreases hepatic triglyceride synthesis
  27. Bumblebee Tuna - Adverse Effects
    anaphylaxis, dyspepsia, eructation, elevated LFTs
  28. Bumblebee Tuna - Monitor
    LFTs
  29. Bumblebee Tuna -Target
    TG (reduce by 45%) and HDL (raise by 9%)
Author
swusops
ID
99689
Card Set
Dyslipidemia - Drugs
Description
Dyslipidemia first exam
Updated